MNKD MannKind Corp

$5.59

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending 2025-09-30
Expected on Nov 11, 2025
Report Time: Unknown Release Time
The Whisper Number
$0.02
Consensus Estimate: $0.02
Revenue Estimate: $80.24M

Latest Earnings Insight

Updated On 10/31/2025

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United States. The company is headquartered in Westlake Village, California.

Website: https://www.mannkindcorp.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
899460
Address
30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE, CA, US
Valuation
Market Cap
$1.38B
P/E Ratio
45.40
PEG Ratio
-0.23
Price to Book
0.00
Performance
EPS
$0.10
Dividend Yield
—
Profit Margin
9.66%
ROE
0.00%
Technicals
50D MA
$5.16
200D MA
$5.95
52W High
$7.63
52W Low
$4.06
Fundamentals
Shares Outstanding
304M
Target Price
$10.29
Beta
1.21

MNKD EPS Estimates vs Actual

● Estimated
● Actual

MNKD News & Sentiment

Oct 30, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Protagonist Therapeutics ( PTGX ) Expected to Beat Earnings Estimates: Should You Buy?
Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oct 13, 2025 • Benzinga NEUTRAL
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application ( sBLA ) for Inhaled Insulin ( Afrezza ) in Children and Adolescents Aged 4-17 Years Living with Diabetes - MannKind ( NASDAQ:MNKD )
If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapy sBLA submission based on data from the Phase 3 INHALE-1 study PDUFA target action date of May 29, 2026
Oct 13, 2025 • GlobeNewswire NEUTRAL
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application ( sBLA ) for Inhaled Insulin ( Afrezza ) in Children and Adolescents Aged 4-17 Years Living with Diabetes
MannKind Announces U.S. FDA Accepts for Review its sBLA for Inhaled Insulin in Children and Adolescents Aged ...
Oct 07, 2025 • GlobeNewswire NEUTRAL
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation ( Nasdaq: MNKD ) successfully completed the previously announced acquisition of scPharmaceuticals Inc.
Oct 07, 2025 • Business Insider SOMEWHAT-BULLISH
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation ( Nasdaq: MNKD ) successfully completed the previously announced acquisition of scPharmaceuticals Inc.
Oct 07, 2025 • Benzinga SOMEWHAT-BULLISH
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care - MannKind ( NASDAQ:MNKD )
DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation ( NASDAQ:MNKD ) successfully completed the previously announced acquisition of scPharmaceuticals Inc.
Sentiment Snapshot

Average Sentiment Score:

0.211
50 articles with scored sentiment

Overall Sentiment:

Bullish

MNKD Reported Earnings

Aug 06, 2025
Jun 30, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.05
  • Estimate: $0.05
  • Whisper: —
  • Surprise %: 0.0%
May 08, 2025
Mar 31, 2025 (Pre market)
-0.02 Surprise
  • Reported EPS: $0.04
  • Estimate: $0.06
  • Whisper: —
  • Surprise %: -33.3%
Feb 26, 2025
Dec 31, 2024 (Pre market)
-0.0 Surprise
  • Reported EPS: $0.03
  • Estimate: $0.03
  • Whisper: —
  • Surprise %: -15.0%
Nov 07, 2024
Sep 30, 2024 (Post market)
0.02 Surprise
  • Reported EPS: $0.05
  • Estimate: $0.03
  • Whisper: —
  • Surprise %: 66.7%
Aug 07, 2024
Jun 30, 2024 (Pre market)
-0.02 Surprise
  • Reported EPS: $-0.01
  • Estimate: $0.01
  • Whisper: —
  • Surprise %: -200.0%
May 08, 2024
Mar 31, 2024 (Post market)
0.01 Surprise
  • Reported EPS: $0.04
  • Estimate: $0.03
  • Whisper: —
  • Surprise %: 33.3%
Feb 27, 2024
Dec 31, 2023 (Post market)
-0.01 Surprise
  • Reported EPS: $0.00
  • Estimate: $0.01
  • Whisper: —
  • Surprise %: -57.0%
Nov 07, 2023
Sep 30, 2023 (Post market)
0.03 Surprise
  • Reported EPS: $0.01
  • Estimate: $-0.02
  • Whisper: —
  • Surprise %: 150.0%
Aug 07, 2023
Jun 30, 2023 (Post market)
0.02 Surprise
  • Reported EPS: $-0.02
  • Estimate: $-0.04
  • Whisper: —
  • Surprise %: 50.0%

Financials